308.78 0.00 (0.00%)
After hours: 5:25PM EDT
|Bid||305.08 x 1100|
|Ask||359.50 x 1200|
|Day's range||307.81 - 317.79|
|52-week range||155.16 - 388.97|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Earnings date||07 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||361.36|
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results from its broad hematology program will be presented at the 26th European Hematology Association 2021 (EHA2021) Virtual Congress being held June 9 – 17, 2021.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. The new drug application was previously granted priority review by the Center for Drug Evaluation (CDE) in July 2020. BeiGene is preparing to launch pamiparib this month.
BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.